Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Creative Funding Options For China; Investors Battle Perception of Home Court Advantage

This article was originally published in PharmAsia News

Executive Summary

The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns

You may also be interested in...



Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs

Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.

Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy

Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.

Related Content

UsernamePublicRestriction

Register

SC078314

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel